Tag Archive for: GSK

A study showed GSK’s experimental drug Blenrep helped extend survival in patients with a type of blood cancer without symptoms worsening, marking a potential comeback for the drug after several setbacks.

The World Health Organization on Tuesday flagged growing HIV drug resistance against GSK and ViiV Healthcare’s antiretroviral medication Tivicay (dolutegravir), noting that observational and survey data suggest that resistance may now be higher than levels observed in clinical trials.

CEO Emma Walmsley’s total pay in 2023 was 12.7 million pounds ($16.05 million), a 51% increase from 2022, thanks to a big jump in performance-related pay, the British drugmaker’s annual report showed on Friday.

British drugmaker GSK said on Monday its oral drug to treat gonorrhea met the main goal of non-inferiority, compared to an existing combination treatment, in a late-stage trial.

ViiV Healthcare and GSK’s Cabenuva in a Phase III study showed superior efficacy versus daily oral antiretroviral treatment in HIV patients with a history of difficulties in taking daily pills.

Moderna fell as much as 7% on Friday after Wall Street analysts raised concerns over faster declines in the efficacy of its experimental respiratory syncytial virus (RSV) vaccine when compared with rival shots from GSK and Pfizer.

Yesterday the company posted findings from an interim analysis of the Phase III DREAMM-7 trial showing that its antibody-drug conjugate Blenrep, when used in a three-drug regimen, led to a significant improvement in progression-free survival in patients with relapsed or refractory multiple myeloma.

The case was set to go to trial on Feb. 20 and instead, will now be dismissed, the British drugmaker said in a statement.

The company beat market estimates for fourth-quarter results today, and unveiled an upbeat forecast for 2024 and beyond on the ramp-up of its vaccines and cancer drugs pipeline, underscoring the benefits of its consumer health unit spin-off.

The British drugmaker said it sold around 300 million shares of Haleon, cutting its shareholding to 4.2%, as it expands its portfolio of specialty medicines.